Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay
Open Access
- 4 March 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3), e0247797
- https://doi.org/10.1371/journal.pone.0247797
Abstract
Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body’s temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31–60 days PSO. By 61–90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1–4 days PSO with 86% positivity observed at 5–7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.Keywords
This publication has 37 references indexed in Scilit:
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of InfluenzaFrontiers in Immunology, 2016
- The immunology of smallpox vaccinesCurrent Opinion in Immunology, 2009
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significanceRespirology, 2006
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990